Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Primary Myelofibrosis | 20 | 2022 | 215 | 1.890 |
Why?
|
Myeloproliferative Disorders | 18 | 2022 | 606 | 1.830 |
Why?
|
Janus Kinase 2 | 26 | 2021 | 528 | 1.630 |
Why?
|
Leukemia, Myeloid, Acute | 30 | 2024 | 3523 | 1.510 |
Why?
|
Polycythemia Vera | 15 | 2022 | 164 | 1.480 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2024 | 1519 | 1.210 |
Why?
|
Thrombocythemia, Essential | 11 | 2022 | 105 | 1.210 |
Why?
|
Myelodysplastic Syndromes | 9 | 2024 | 1352 | 0.660 |
Why?
|
fms-Like Tyrosine Kinase 3 | 7 | 2023 | 491 | 0.570 |
Why?
|
Hepatic Veno-Occlusive Disease | 4 | 2006 | 220 | 0.510 |
Why?
|
Protein Kinase Inhibitors | 15 | 2023 | 5535 | 0.490 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2021 | 689 | 0.480 |
Why?
|
Antineoplastic Agents | 20 | 2022 | 13695 | 0.450 |
Why?
|
Pyrimidines | 9 | 2020 | 2942 | 0.400 |
Why?
|
Hematopoietic Stem Cell Transplantation | 12 | 2022 | 5442 | 0.390 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2020 | 222 | 0.390 |
Why?
|
Leukemia, Myeloid | 3 | 2019 | 707 | 0.370 |
Why?
|
Antibodies, Bispecific | 3 | 2021 | 164 | 0.370 |
Why?
|
Fusion Proteins, bcr-abl | 4 | 2021 | 434 | 0.360 |
Why?
|
Janus Kinases | 5 | 2020 | 244 | 0.360 |
Why?
|
Remission Induction | 14 | 2023 | 2386 | 0.350 |
Why?
|
Point Mutation | 4 | 2010 | 1623 | 0.340 |
Why?
|
Hematologic Neoplasms | 6 | 2018 | 1832 | 0.330 |
Why?
|
Asparaginase | 2 | 2024 | 236 | 0.320 |
Why?
|
Protein-Tyrosine Kinases | 7 | 2006 | 2455 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2024 | 11524 | 0.290 |
Why?
|
Enzyme Inhibitors | 2 | 2010 | 3798 | 0.290 |
Why?
|
Aminoglycosides | 2 | 2006 | 162 | 0.280 |
Why?
|
Mutation, Missense | 6 | 2011 | 2564 | 0.270 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2009 | 648 | 0.270 |
Why?
|
Geriatric Assessment | 3 | 2022 | 1372 | 0.260 |
Why?
|
Transplantation, Homologous | 9 | 2022 | 4776 | 0.260 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 903 | 0.260 |
Why?
|
World Health Organization | 1 | 2010 | 1318 | 0.240 |
Why?
|
Hematopoietic Cell Growth Factors | 2 | 2022 | 102 | 0.230 |
Why?
|
Neutropenia | 1 | 2009 | 895 | 0.230 |
Why?
|
Mutation | 20 | 2021 | 29786 | 0.230 |
Why?
|
Philadelphia Chromosome | 3 | 2022 | 112 | 0.230 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 2 | 2013 | 38 | 0.220 |
Why?
|
Benzamides | 4 | 2017 | 1379 | 0.210 |
Why?
|
Proto-Oncogene Proteins | 9 | 2014 | 4554 | 0.200 |
Why?
|
Medical Oncology | 5 | 2022 | 2265 | 0.190 |
Why?
|
Blast Crisis | 3 | 2011 | 103 | 0.190 |
Why?
|
Leukemia, Promyelocytic, Acute | 2 | 2013 | 236 | 0.190 |
Why?
|
Hypertriglyceridemia | 1 | 2023 | 293 | 0.180 |
Why?
|
Humans | 107 | 2024 | 744343 | 0.180 |
Why?
|
Aged, 80 and over | 32 | 2021 | 57776 | 0.180 |
Why?
|
Myeloid Cells | 3 | 2017 | 810 | 0.170 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 2 | 2011 | 97 | 0.170 |
Why?
|
STAT Transcription Factors | 3 | 2018 | 182 | 0.170 |
Why?
|
Prognosis | 22 | 2023 | 29063 | 0.170 |
Why?
|
Leukemia | 3 | 2016 | 1511 | 0.170 |
Why?
|
Aged | 47 | 2024 | 163280 | 0.170 |
Why?
|
Mycoses | 1 | 2022 | 376 | 0.160 |
Why?
|
Neoplasms | 7 | 2022 | 21683 | 0.160 |
Why?
|
Amino Acid Substitution | 6 | 2011 | 1791 | 0.160 |
Why?
|
Thrombocytosis | 4 | 2017 | 81 | 0.160 |
Why?
|
Middle Aged | 49 | 2022 | 213383 | 0.160 |
Why?
|
Tandem Repeat Sequences | 2 | 2016 | 185 | 0.150 |
Why?
|
Piperazines | 4 | 2016 | 2488 | 0.150 |
Why?
|
Janus Kinase 1 | 1 | 2017 | 104 | 0.150 |
Why?
|
Adult | 46 | 2024 | 214055 | 0.150 |
Why?
|
Mastocytosis, Systemic | 1 | 2018 | 100 | 0.150 |
Why?
|
Sulfonamides | 2 | 2024 | 1938 | 0.150 |
Why?
|
Receptors, Thrombopoietin | 4 | 2016 | 157 | 0.150 |
Why?
|
Molecular Targeted Therapy | 6 | 2019 | 2727 | 0.150 |
Why?
|
Survival Rate | 12 | 2022 | 12788 | 0.140 |
Why?
|
Disease-Free Survival | 8 | 2023 | 6895 | 0.140 |
Why?
|
Recombinant Fusion Proteins | 2 | 2024 | 3772 | 0.140 |
Why?
|
Cytarabine | 5 | 2019 | 692 | 0.140 |
Why?
|
Eosinophilia | 1 | 2020 | 541 | 0.140 |
Why?
|
Lethargy | 1 | 2015 | 39 | 0.130 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.130 |
Why?
|
Arabinonucleosides | 1 | 2014 | 35 | 0.130 |
Why?
|
Adenine Nucleotides | 1 | 2014 | 121 | 0.130 |
Why?
|
Gene Frequency | 3 | 2018 | 3588 | 0.130 |
Why?
|
Diagnostic Self Evaluation | 1 | 2016 | 230 | 0.120 |
Why?
|
Male | 53 | 2021 | 350118 | 0.120 |
Why?
|
Niacinamide | 1 | 2016 | 417 | 0.120 |
Why?
|
Stem Cell Transplantation | 3 | 2018 | 1620 | 0.120 |
Why?
|
Female | 56 | 2021 | 380194 | 0.120 |
Why?
|
Quality of Life | 7 | 2023 | 12804 | 0.120 |
Why?
|
Early Termination of Clinical Trials | 1 | 2013 | 68 | 0.120 |
Why?
|
Watchful Waiting | 1 | 2018 | 492 | 0.120 |
Why?
|
Receptor, Notch2 | 1 | 2014 | 89 | 0.120 |
Why?
|
Survival Analysis | 9 | 2018 | 10252 | 0.110 |
Why?
|
Young Adult | 18 | 2024 | 56430 | 0.110 |
Why?
|
STAT5 Transcription Factor | 1 | 2014 | 259 | 0.110 |
Why?
|
Treatment Outcome | 21 | 2020 | 63114 | 0.110 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 528 | 0.110 |
Why?
|
Translocation, Genetic | 3 | 2009 | 1420 | 0.110 |
Why?
|
Pyrazoles | 2 | 2020 | 1972 | 0.110 |
Why?
|
Anemia | 1 | 2022 | 1506 | 0.110 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2073 | 0.100 |
Why?
|
Serotonin Syndrome | 1 | 2012 | 18 | 0.100 |
Why?
|
Clinical Protocols | 1 | 2018 | 1462 | 0.100 |
Why?
|
Proline | 1 | 2013 | 458 | 0.100 |
Why?
|
Retrospective Studies | 19 | 2022 | 77449 | 0.100 |
Why?
|
Azacitidine | 2 | 2024 | 347 | 0.100 |
Why?
|
Alternative Splicing | 2 | 2014 | 1117 | 0.100 |
Why?
|
Methylene Blue | 1 | 2012 | 155 | 0.100 |
Why?
|
Aminopyridines | 1 | 2015 | 542 | 0.100 |
Why?
|
Ifosfamide | 1 | 2012 | 228 | 0.100 |
Why?
|
Receptors, Cytokine | 2 | 2009 | 261 | 0.100 |
Why?
|
Anaphylaxis | 1 | 2018 | 746 | 0.100 |
Why?
|
Dexamethasone | 2 | 2015 | 1951 | 0.100 |
Why?
|
Signal Transduction | 9 | 2023 | 23403 | 0.100 |
Why?
|
Affect | 1 | 2019 | 1476 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2016 | 3557 | 0.100 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 640 | 0.100 |
Why?
|
Calreticulin | 3 | 2016 | 98 | 0.090 |
Why?
|
Drug Administration Schedule | 5 | 2020 | 4933 | 0.090 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2017 | 1676 | 0.090 |
Why?
|
Adolescent | 18 | 2024 | 85781 | 0.090 |
Why?
|
Hospitalization | 3 | 2021 | 10262 | 0.090 |
Why?
|
Hydroxamic Acids | 1 | 2013 | 494 | 0.090 |
Why?
|
Tretinoin | 1 | 2013 | 517 | 0.090 |
Why?
|
Benzimidazoles | 1 | 2015 | 850 | 0.090 |
Why?
|
Severity of Illness Index | 3 | 2020 | 15540 | 0.090 |
Why?
|
Needs Assessment | 1 | 2016 | 1147 | 0.090 |
Why?
|
Antibodies, Monoclonal | 2 | 2006 | 9274 | 0.090 |
Why?
|
Neurotoxicity Syndromes | 1 | 2013 | 290 | 0.090 |
Why?
|
Patients | 1 | 2016 | 900 | 0.090 |
Why?
|
Intensive Care Units | 2 | 2021 | 3679 | 0.090 |
Why?
|
Anthracyclines | 2 | 2023 | 288 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2020 | 5172 | 0.080 |
Why?
|
RNA Splicing | 1 | 2013 | 907 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2019 | 1439 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1380 | 0.080 |
Why?
|
Patient Selection | 1 | 2020 | 4215 | 0.080 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2009 | 367 | 0.080 |
Why?
|
Thrombosis | 3 | 2018 | 2968 | 0.080 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2013 | 789 | 0.080 |
Why?
|
Headache | 1 | 2015 | 1226 | 0.080 |
Why?
|
Patient Care Team | 1 | 2018 | 2531 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1356 | 0.070 |
Why?
|
Maximum Tolerated Dose | 3 | 2017 | 892 | 0.070 |
Why?
|
Lymphoma | 1 | 2016 | 1877 | 0.070 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2009 | 658 | 0.070 |
Why?
|
Neoplasms, Second Primary | 1 | 2014 | 1061 | 0.070 |
Why?
|
Vincristine | 2 | 2022 | 1039 | 0.070 |
Why?
|
Risk Factors | 12 | 2021 | 72290 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2013 | 9239 | 0.070 |
Why?
|
Nuclear Proteins | 2 | 2018 | 5853 | 0.070 |
Why?
|
Tenascin | 1 | 2005 | 59 | 0.070 |
Why?
|
DNA Mutational Analysis | 6 | 2014 | 4186 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2019 | 5317 | 0.070 |
Why?
|
Fatigue | 2 | 2017 | 1531 | 0.060 |
Why?
|
Thiazoles | 1 | 2012 | 1483 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2003 | 7181 | 0.060 |
Why?
|
Indoles | 1 | 2013 | 1839 | 0.060 |
Why?
|
Retreatment | 2 | 2016 | 610 | 0.060 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2010 | 871 | 0.060 |
Why?
|
Splenomegaly | 2 | 2015 | 190 | 0.060 |
Why?
|
Catalysis | 1 | 2006 | 761 | 0.060 |
Why?
|
Combined Modality Therapy | 4 | 2017 | 8642 | 0.060 |
Why?
|
Chromosomes, Human, X | 1 | 2006 | 296 | 0.060 |
Why?
|
Follow-Up Studies | 9 | 2019 | 39050 | 0.060 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2005 | 299 | 0.060 |
Why?
|
Oncogene Proteins, Fusion | 3 | 2020 | 1581 | 0.060 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 1 | 2024 | 39 | 0.060 |
Why?
|
Nitriles | 2 | 2020 | 956 | 0.060 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2005 | 188 | 0.060 |
Why?
|
Adenosine Triphosphate | 1 | 2010 | 2025 | 0.060 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2004 | 185 | 0.060 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 2 | 2018 | 98 | 0.060 |
Why?
|
Recurrence | 4 | 2018 | 8340 | 0.060 |
Why?
|
Staurosporine | 1 | 2004 | 251 | 0.060 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2005 | 403 | 0.060 |
Why?
|
Terminal Care | 1 | 2015 | 1694 | 0.060 |
Why?
|
Acute Disease | 3 | 2019 | 7149 | 0.060 |
Why?
|
Cell Lineage | 2 | 2016 | 2504 | 0.060 |
Why?
|
Enzyme Activation | 2 | 2006 | 3701 | 0.060 |
Why?
|
Bone Marrow | 4 | 2018 | 2948 | 0.060 |
Why?
|
Transplantation Conditioning | 2 | 2022 | 1598 | 0.050 |
Why?
|
Boronic Acids | 3 | 2013 | 965 | 0.050 |
Why?
|
Neoplasm Proteins | 2 | 2016 | 3703 | 0.050 |
Why?
|
Hematopoiesis | 3 | 2009 | 2072 | 0.050 |
Why?
|
DNA-Binding Proteins | 2 | 2011 | 9648 | 0.050 |
Why?
|
Clone Cells | 1 | 2006 | 1692 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7279 | 0.050 |
Why?
|
Brain Diseases | 1 | 2012 | 1563 | 0.050 |
Why?
|
B-Lymphocytes | 3 | 2021 | 4665 | 0.050 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 2 | 2018 | 379 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2015 | 3022 | 0.050 |
Why?
|
Pyrazines | 3 | 2013 | 1230 | 0.050 |
Why?
|
Homozygote | 3 | 2014 | 1785 | 0.050 |
Why?
|
Cell Differentiation | 2 | 2021 | 11483 | 0.050 |
Why?
|
Microcirculation | 1 | 2005 | 1286 | 0.050 |
Why?
|
Incidence | 4 | 2023 | 20947 | 0.050 |
Why?
|
Gene Expression Profiling | 5 | 2016 | 9438 | 0.050 |
Why?
|
Phenotype | 4 | 2016 | 16365 | 0.050 |
Why?
|
Stromal Cells | 1 | 2005 | 1355 | 0.040 |
Why?
|
Karyotyping | 2 | 2014 | 1243 | 0.040 |
Why?
|
Drug Synergism | 2 | 2015 | 1792 | 0.040 |
Why?
|
Blood Vessels | 1 | 2005 | 1125 | 0.040 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2019 | 27 | 0.040 |
Why?
|
Terminology as Topic | 1 | 2007 | 1547 | 0.040 |
Why?
|
Organizations, Nonprofit | 1 | 2020 | 104 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 692 | 0.040 |
Why?
|
Databases, Factual | 1 | 2014 | 7729 | 0.040 |
Why?
|
Polymerase Chain Reaction | 3 | 2019 | 6171 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6622 | 0.040 |
Why?
|
Comorbidity | 3 | 2022 | 10388 | 0.040 |
Why?
|
Histamine Antagonists | 1 | 2018 | 93 | 0.040 |
Why?
|
Age Factors | 5 | 2020 | 18370 | 0.040 |
Why?
|
Prospective Studies | 6 | 2023 | 53288 | 0.040 |
Why?
|
Dioxygenases | 2 | 2011 | 316 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2019 | 13989 | 0.040 |
Why?
|
Protein Conformation | 1 | 2006 | 4011 | 0.040 |
Why?
|
Bone Marrow Cells | 2 | 2021 | 2513 | 0.040 |
Why?
|
Physicians | 1 | 2016 | 4567 | 0.040 |
Why?
|
Genomics | 1 | 2014 | 5720 | 0.040 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2005 | 1381 | 0.040 |
Why?
|
Models, Biological | 1 | 2014 | 9583 | 0.040 |
Why?
|
Animals | 8 | 2018 | 168757 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2017 | 152 | 0.040 |
Why?
|
Hydrolases | 1 | 2018 | 139 | 0.040 |
Why?
|
Sequence Deletion | 3 | 2009 | 1526 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2010 | 7913 | 0.040 |
Why?
|
Antifungal Agents | 1 | 2022 | 730 | 0.040 |
Why?
|
Activities of Daily Living | 2 | 2022 | 2418 | 0.040 |
Why?
|
Genetic Testing | 1 | 2010 | 3444 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 1434 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2014 | 2715 | 0.040 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2004 | 1660 | 0.040 |
Why?
|
United States Food and Drug Administration | 2 | 2020 | 1584 | 0.040 |
Why?
|
Anxiety | 2 | 2023 | 4297 | 0.040 |
Why?
|
Withholding Treatment | 1 | 2020 | 599 | 0.030 |
Why?
|
Etoposide | 1 | 2017 | 641 | 0.030 |
Why?
|
DNA Nucleotidylexotransferase | 1 | 2015 | 64 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 246 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2018 | 10481 | 0.030 |
Why?
|
Administration, Oral | 2 | 2013 | 3913 | 0.030 |
Why?
|
Mental Disorders | 1 | 2015 | 6600 | 0.030 |
Why?
|
Sphingosine | 1 | 1997 | 307 | 0.030 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 21 | 0.030 |
Why?
|
Piracetam | 1 | 2015 | 87 | 0.030 |
Why?
|
Spleen | 2 | 2015 | 2362 | 0.030 |
Why?
|
Mice | 6 | 2018 | 81183 | 0.030 |
Why?
|
Self Report | 2 | 2017 | 3558 | 0.030 |
Why?
|
Transcription Factors | 2 | 2014 | 12208 | 0.030 |
Why?
|
Cytoprotection | 1 | 2015 | 210 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2018 | 21746 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2018 | 776 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 12261 | 0.030 |
Why?
|
Endothelium, Vascular | 2 | 2004 | 4456 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 367 | 0.030 |
Why?
|
Nootropic Agents | 1 | 2015 | 160 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2014 | 192 | 0.030 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 840 | 0.030 |
Why?
|
Exons | 2 | 2011 | 2437 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1677 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2018 | 1880 | 0.030 |
Why?
|
Disease Progression | 5 | 2012 | 13284 | 0.030 |
Why?
|
Hydroxyurea | 1 | 2015 | 290 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 755 | 0.030 |
Why?
|
Granulocytes | 2 | 2006 | 548 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 380 | 0.030 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11031 | 0.030 |
Why?
|
Risk Assessment | 4 | 2017 | 23338 | 0.030 |
Why?
|
DNA, Neoplasm | 2 | 2011 | 1758 | 0.030 |
Why?
|
Drug Approval | 1 | 2020 | 742 | 0.030 |
Why?
|
Time Factors | 4 | 2019 | 40075 | 0.030 |
Why?
|
Daunorubicin | 1 | 2012 | 158 | 0.030 |
Why?
|
Logistic Models | 2 | 2019 | 13408 | 0.030 |
Why?
|
Child | 4 | 2024 | 77709 | 0.030 |
Why?
|
Overweight | 1 | 2023 | 2371 | 0.030 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2012 | 318 | 0.030 |
Why?
|
Germ-Line Mutation | 2 | 2011 | 1788 | 0.030 |
Why?
|
Ribonucleoproteins | 1 | 2014 | 381 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2085 | 0.030 |
Why?
|
Drug Costs | 1 | 2020 | 1105 | 0.030 |
Why?
|
United States | 5 | 2022 | 69872 | 0.030 |
Why?
|
Repressor Proteins | 2 | 2014 | 3023 | 0.030 |
Why?
|
Perception | 1 | 2018 | 1198 | 0.030 |
Why?
|
Azepines | 1 | 2014 | 336 | 0.030 |
Why?
|
Peripheral Nervous System | 1 | 2012 | 150 | 0.020 |
Why?
|
Body Mass Index | 2 | 2023 | 12720 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1878 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2429 | 0.020 |
Why?
|
Depression | 2 | 2023 | 7766 | 0.020 |
Why?
|
Cell Line, Tumor | 3 | 2015 | 16689 | 0.020 |
Why?
|
Mast Cells | 1 | 2018 | 1544 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 12354 | 0.020 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2013 | 474 | 0.020 |
Why?
|
Molecular Sequence Annotation | 1 | 2013 | 528 | 0.020 |
Why?
|
Research Design | 2 | 2018 | 5987 | 0.020 |
Why?
|
Craniotomy | 1 | 2015 | 729 | 0.020 |
Why?
|
Salvage Therapy | 1 | 2017 | 1275 | 0.020 |
Why?
|
Cytokines | 3 | 2013 | 7322 | 0.020 |
Why?
|
Inverted Repeat Sequences | 1 | 2010 | 61 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2014 | 2942 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3670 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2011 | 295 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5007 | 0.020 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2014 | 651 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2459 | 0.020 |
Why?
|
Internet | 2 | 2016 | 3064 | 0.020 |
Why?
|
Life Expectancy | 1 | 2016 | 1184 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8324 | 0.020 |
Why?
|
Hemoglobins | 2 | 2006 | 1534 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1574 | 0.020 |
Why?
|
Metaphase | 1 | 2009 | 151 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1655 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2016 | 2453 | 0.020 |
Why?
|
Genotype | 3 | 2011 | 12951 | 0.020 |
Why?
|
Heterozygote | 2 | 2006 | 2804 | 0.020 |
Why?
|
Cohort Studies | 4 | 2015 | 40561 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2015 | 1836 | 0.020 |
Why?
|
Idarubicin | 1 | 2008 | 62 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2021 | 3386 | 0.020 |
Why?
|
Triazoles | 1 | 2014 | 911 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2012 | 1475 | 0.020 |
Why?
|
Thalidomide | 1 | 2013 | 890 | 0.020 |
Why?
|
Trisomy | 1 | 2009 | 266 | 0.020 |
Why?
|
Codon, Nonsense | 1 | 2009 | 281 | 0.020 |
Why?
|
Mixed Function Oxygenases | 1 | 2009 | 272 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2234 | 0.020 |
Why?
|
Benzodiazepines | 1 | 2014 | 1101 | 0.020 |
Why?
|
Methotrexate | 1 | 2014 | 1727 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2618 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2014 | 1783 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2038 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2013 | 956 | 0.020 |
Why?
|
Sequence Analysis, DNA | 2 | 2011 | 4803 | 0.020 |
Why?
|
Fibrinogen | 1 | 2010 | 894 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2009 | 17446 | 0.020 |
Why?
|
Frameshift Mutation | 1 | 2009 | 399 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2015 | 1524 | 0.020 |
Why?
|
Syndrome | 1 | 2013 | 3251 | 0.020 |
Why?
|
Biopsy | 1 | 2018 | 6756 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3743 | 0.020 |
Why?
|
Saccharomyces cerevisiae | 1 | 1997 | 2752 | 0.020 |
Why?
|
Mice, Inbred BALB C | 2 | 2006 | 6386 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9313 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2011 | 2124 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2011 | 15519 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 2006 | 356 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1799 | 0.020 |
Why?
|
Immunotoxins | 1 | 2006 | 179 | 0.020 |
Why?
|
Sex Chromosome Aberrations | 1 | 2006 | 114 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2014 | 2440 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6538 | 0.020 |
Why?
|
Cell Line | 2 | 2014 | 15997 | 0.020 |
Why?
|
Alleles | 1 | 2016 | 6933 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3229 | 0.020 |
Why?
|
GPI-Linked Proteins | 1 | 2006 | 434 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 3505 | 0.020 |
Why?
|
Transformation, Genetic | 1 | 2004 | 192 | 0.020 |
Why?
|
Bone Marrow Diseases | 1 | 2006 | 231 | 0.020 |
Why?
|
Decision Making | 1 | 2018 | 3887 | 0.020 |
Why?
|
Phosphorylation | 2 | 2006 | 8436 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2013 | 1889 | 0.010 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2004 | 197 | 0.010 |
Why?
|
Transcription, Genetic | 2 | 2009 | 7722 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2006 | 629 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2008 | 2327 | 0.010 |
Why?
|
Cell Survival | 1 | 2014 | 5882 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9849 | 0.010 |
Why?
|
Isoantigens | 1 | 2006 | 567 | 0.010 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2004 | 250 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2014 | 3462 | 0.010 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2006 | 469 | 0.010 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2004 | 460 | 0.010 |
Why?
|
Pruritus | 1 | 2006 | 361 | 0.010 |
Why?
|
Zinc Fingers | 1 | 2004 | 585 | 0.010 |
Why?
|
Mouth Mucosa | 1 | 2005 | 434 | 0.010 |
Why?
|
Megakaryocytes | 1 | 2006 | 545 | 0.010 |
Why?
|
Leukocyte Count | 1 | 2005 | 1588 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12745 | 0.010 |
Why?
|
Palliative Care | 1 | 2016 | 3493 | 0.010 |
Why?
|
Membrane Proteins | 2 | 2014 | 7880 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2009 | 4740 | 0.010 |
Why?
|
DNA Primers | 1 | 2005 | 2892 | 0.010 |
Why?
|
Recombination, Genetic | 1 | 2005 | 1586 | 0.010 |
Why?
|
Prevalence | 1 | 2016 | 15226 | 0.010 |
Why?
|
Mitosis | 1 | 2005 | 1208 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 9959 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3920 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2005 | 4320 | 0.010 |
Why?
|
Apoptosis | 1 | 2015 | 9727 | 0.010 |
Why?
|
Cell Division | 1 | 2006 | 4568 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2016 | 10180 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2005 | 2649 | 0.010 |
Why?
|
Risk | 1 | 2010 | 9687 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2006 | 1990 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 2006 | 2765 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2014 | 8428 | 0.010 |
Why?
|
Data Collection | 1 | 2007 | 3341 | 0.010 |
Why?
|
Disabled Persons | 1 | 2007 | 1212 | 0.010 |
Why?
|
Transfection | 1 | 2005 | 5892 | 0.010 |
Why?
|
Genetic Vectors | 1 | 2006 | 3420 | 0.010 |
Why?
|
Sphingolipids | 1 | 1997 | 159 | 0.010 |
Why?
|
Motor Activity | 1 | 2007 | 2714 | 0.010 |
Why?
|
Medicare | 1 | 2014 | 6566 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2006 | 18029 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2006 | 2866 | 0.010 |
Why?
|
Genome, Human | 1 | 2009 | 4420 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 19905 | 0.010 |
Why?
|
Membrane Glycoproteins | 1 | 2006 | 3768 | 0.010 |
Why?
|
Models, Molecular | 1 | 2005 | 5456 | 0.010 |
Why?
|
Drug Resistance, Microbial | 1 | 1997 | 862 | 0.010 |
Why?
|
Open Reading Frames | 1 | 1997 | 810 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2005 | 3474 | 0.010 |
Why?
|
Base Sequence | 1 | 2005 | 12797 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2005 | 13815 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20129 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 12245 | 0.010 |
Why?
|
Chronic Disease | 1 | 2007 | 9146 | 0.010 |
Why?
|
Algorithms | 1 | 2011 | 13881 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2006 | 19229 | 0.010 |
Why?
|
Genetic Variation | 1 | 2004 | 6544 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 35421 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 12072 | 0.000 |
Why?
|
Child, Preschool | 1 | 2006 | 41006 | 0.000 |
Why?
|